153 related articles for article (PubMed ID: 4064050)
1. Optimizing tumor markers in breast cancer: monitoring, prognosis, and therapy control.
Staab HJ; Ahlemann LM; Anderer FA; Zwirner M; Schindler AE
Cancer Detect Prev; 1985; 8(1-2):35-45. PubMed ID: 4064050
[TBL] [Abstract][Full Text] [Related]
2. [The tumor markers CEA, TPA and CA 19-9 and ferritin and osteocalcin in follow-up studies in breast cancer].
Schatz C; von Lieven H; Mulders M; Rowold J; Stracke H; Müller H; Grebe SF; Schatz H
Wien Klin Wochenschr; 1985 Dec; 97(23):873-9. PubMed ID: 3878042
[TBL] [Abstract][Full Text] [Related]
3. [Clinical significance of a tumor marker NCC-ST-439 in breast cancer--a comparative study with CA 15-3, CEA and TPA].
Okamura Y; Takatsuka Y; Katoh T; Tsumura I; Kobayakawa K; Kawahara T
Gan To Kagaku Ryoho; 1991 Jul; 18(8):1279-85. PubMed ID: 2069399
[TBL] [Abstract][Full Text] [Related]
4. Clinical evaluation of a panel of mRNA markers in the detection of disseminated tumor cells in patients with operable breast cancer.
Varangot M; Barrios E; Sóñora C; Aizen B; Pressa C; Estrugo R; Lavigna R; Musé I; Osinaga E; Berois N
Oncol Rep; 2005 Aug; 14(2):537-45. PubMed ID: 16012742
[TBL] [Abstract][Full Text] [Related]
5. [The tumor markers TPA and CEA in the after care of breast cancer].
Beaufort F; Fueger GF; Steiner H
Wien Med Wochenschr; 1985 Feb; 135(4):85-8. PubMed ID: 2986366
[TBL] [Abstract][Full Text] [Related]
6. Comparison of serum CEA, PHI, and TPA as tumor markers in breast cancer patients.
Paulick R; Caffier H; Paulick M
Cancer Detect Prev; 1987; 10(3-4):197-203. PubMed ID: 3568016
[TBL] [Abstract][Full Text] [Related]
7. Serum tumor markers in colorectal cancer staging, grading, and follow-up.
Plebani M; De Paoli M; Basso D; Roveroni G; Giacomini A; Galeotti F; Corsini A
J Surg Oncol; 1996 Aug; 62(4):239-44. PubMed ID: 8691835
[TBL] [Abstract][Full Text] [Related]
8. [Tissue polypeptide and carcinoembryonic antigens in patients with breast cancer].
Polevaia EB; Tkacheva GA; Ivanov VM; Koposova TL
Vopr Onkol; 1984; 30(3):9-13. PubMed ID: 6710954
[TBL] [Abstract][Full Text] [Related]
9. Carcinoembryonic antigen in tissue and serum from breast cancer patients relationship with steroid receptors and clinical applications in the prognosis and early diagnosis of relapse.
Molina R; Farrus B; Filella X; Jo J; Zanón G; Pahisa J; Latre M; Muñoz M; Ballesta AM
Anticancer Res; 1999; 19(4A):2557-62. PubMed ID: 10470194
[TBL] [Abstract][Full Text] [Related]
10. Molecular detection of disseminated breast cancer cells in the bone marrow of early breast cancer patients using quantitative RT PCR for CEA.
Janku F; Srovnal J; Korinkova G; Novotny J; Petruzelka L; Power D; Matous B; Hajduch M
Neoplasma; 2008; 55(4):317-22. PubMed ID: 18505343
[TBL] [Abstract][Full Text] [Related]
11. Circulating tumor markers in breast cancer (review).
Jotti GS; Bombardieri E
Anticancer Res; 1990; 10(1):253-8. PubMed ID: 2185687
[TBL] [Abstract][Full Text] [Related]
12. [Diagnostic value of combined detection of TPS, CA153 and CEA in breast cancer].
Zheng H; Luo RC
Di Yi Jun Yi Da Xue Xue Bao; 2005 Oct; 25(10):1293-4, 1298. PubMed ID: 16234113
[TBL] [Abstract][Full Text] [Related]
13. [Human breast cancer markers].
Remennik LV
Eksp Onkol; 1985; 7(4):3-8. PubMed ID: 2994992
[TBL] [Abstract][Full Text] [Related]
14. Significance of carcinoembryonic and tissue polypeptide antigen determination in the diagnosis of metastases in breast cancer.
Kausitz J; Hupka S; Makaiová I; Michalíková B; Urbanová M; Bohunický L; Belovicová C
Neoplasma; 1986; 33(4):471-6. PubMed ID: 3762808
[TBL] [Abstract][Full Text] [Related]
15. [Estimates of circulating breast cancer-associated antigen CA 15-3 as a monitoring marker in patients with breast cancer].
Yoshimoto M; Akiyama F; Watanabe S; Kasumi F; Fukami A; Nakajima T; Nishi M; Kajitani T; Takahashi S
Gan To Kagaku Ryoho; 1987 Jul; 14(7):2310-5. PubMed ID: 3475042
[TBL] [Abstract][Full Text] [Related]
16. Chemiluminometric determination of tissue polypeptide antigen (TPA), cancer antigen 15-3 (CA 15-3), carcinoembryonic antigen (CEA) in comparison with vascular endothelial growth factor (VEGF) in follow-up of breast cancer.
Findeisen R; Albrecht S; Richter B; Deutschmann K; Zimmermann T; Distler W
Luminescence; 2000; 15(5):283-9. PubMed ID: 11038485
[TBL] [Abstract][Full Text] [Related]
17. Breast cancer and neoadjuvant therapy: any predictive marker?
Vyzula R; Dusek L; Zaloudík J; Demlová R; Klimes D; Selvekerová S
Neoplasma; 2004; 51(6):471-80. PubMed ID: 15640958
[TBL] [Abstract][Full Text] [Related]
18. [Clinical importance of determination of tumor markers during follow-up in breast carcinoma].
Fínek J; Holubec L; Topolcan O; Pikner R; Sůvová B; Treska V
Cas Lek Cesk; 2004; 143(3):174-7. PubMed ID: 15134036
[TBL] [Abstract][Full Text] [Related]
19. [Clinical usefulness of tumor markers in breast cancer].
Konishi K; Karaki K; Watanabe K; Tsuda H; Konishi F
Rinsho Byori; 1993 Oct; 41(10):1108-15. PubMed ID: 8254956
[TBL] [Abstract][Full Text] [Related]
20. mRNA markers of breast cancer nodal metastases: comparison between mammaglobin and carcinoembryonic antigen in 248 patients.
Marchetti A; Buttitta F; Bertacca G; Zavaglia K; Bevilacqua G; Angelucci D; Viacava P; Naccarato A; Bonadio A; Barassi F; Felicioni L; Salvatore S; Mucilli F
J Pathol; 2001 Sep; 195(2):186-90. PubMed ID: 11592097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
